NFKB1 and hepatocellular carcinoma: Taken together, our findings provide an alternative therapeutic target in the NF-κB pathway to reduce the immunodeficiency caused by NF-κB inhibition, which leads to a novel therapeutic strategy for HBV-association HCC and other chronic inflammatory diseases.